Stephanie Stock

University Hospital Cologne

Papers

1

Total Citations

3

H-Index

1

About

Stephanie Stock is a leading health economist whose research centers on health technology assessment, cost-effectiveness analysis, and the value-based implementation of innovative medical technologies. Her work is distinguished by rigorous evaluations that directly inform clinical and policy decisions, particularly in oncology and chronic disease management. A prime example is her highly cited 2025 cost–utility analysis of MR imaging-guided transurethral ultrasound ablation for low- to intermediate-risk localized prostate cancer. This study, which has already garnered significant attention, provides crucial economic evidence supporting the adoption of a novel focal therapy that reduces adverse effects compared to established treatments. By quantifying the balance between clinical benefits and healthcare costs, Stock’s research bridges the gap between technological innovation and practical, large-scale implementation. Her contributions are vital for ensuring that new, patient-friendly therapies are not only clinically effective but also economically sustainable, making her a key voice in shaping efficient, patient-centered healthcare systems.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Cost–utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer
3 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: University Hospital Cologne

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago